OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-07-01 to 2026-07-01.)

Article	Citations
Tasadenoturev active in DIPG	1295
From little subclones grow mighty oaks	1262
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	886
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	876
Sacituzumab govitecan plus pembrolizumab improves outcomes	829
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	709
A new standard of care for advanced-stage urothelial carcinoma	696
Novel ICI–TKI combination improves HCC outcomes	618
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	577
A prioritization framework for large-scale cancer screening under resource constraints: three ‘not all’ principles	567
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	539
Hodgkin lymphoma: great progress with room for improvement	525
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown	504
Current understanding and management of CAR T cell-associated toxicities	498
Achieving control of nasopharyngeal carcinoma: the role of Epstein–Barr virus-based screening and vaccines	489
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	481
Ecological management of the microbiota in patients with cancer	418
Gut microbiota in colorectal cancer development and therapy	385
Ponatinib superior to imatinib in Ph+ ALL	359
Mortality is similar with active monitoring	343
From ESMO 2022	337
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials	337
Belzutifan as a new option in pheochromocytomas and paragangliomas	335
Emerging trends in the global burden of colorectal cancer	332
Understanding and overcoming multidrug resistance in cancer	330

Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	327
Sacituzumab tirumotecan improves OS in mTNBC	326
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC	325
Humanized mouse models for immuno-oncology research	321
Minimal residual disease as a target for liquid biopsy in patients with solid tumours	309
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC	290
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer	281
Craniospinal irradiation improves leptomeningeal metastasis control	270
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours	266
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs	257
Vebreltinib effective in MET-amplified NSCLC	257
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease	251
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma	246
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests	225
Improving outcomes in patients with oesophageal cancer	221
Biomarkers for immunotherapy of hepatocellular carcinoma	210
Unresectable stage III non-small-cell lung cancer: state of the art and challenges	205
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response	202
MicroRNAs in oncology: a translational perspective in the era of AI	200
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship	198
Spatial landscapes of cancers: insights and opportunities	191
Approvals in 2022: overall survival, dose optimization, new approvals and beyond	177
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC	172
Reply to ‘Radiomics Quality Score 2.0: what changed from version 1.0 and why it matters’	170
Women with clinically node negative breast cancer can safely avoid axillary surgery	170
Domvanalimab plus zimberelimab shows promise in upper-tract cancers	166
Iza-bren shows promise in recurrent or metastatic nasopharyngeal carcinoma	147
Prospective comparisons support the use of navigational bronchoscopy	145
DREAMseq of therapy for BRAF-mutant melanoma	143
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC	143
From ESMO 2023: advances in lung cancer	142
Targeting chromosomal instability in patients with cancer	140
First-line zanidatamab–chemotherapy with or without tislelizumab improves survival in advanced-stage HER2+ GEA	136
Synergistic integration of regional and systemic therapies in uveal melanoma	134
Mitigating acute chemotherapy-associated adverse events in patients with cancer	129
Circulating tumour DNA — looking beyond the blood	124
Long-term outcomes following CAR T cell therapy: what we know so far	123
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM	123
Multiomics STEP up in correlative analysis of response to CAR T cells	122
From the ESMO Congress 2023	120
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress	116
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas	116
Author Correction: Innovative approaches for lung cancer screening and interception	114
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC	111
Sentinel lymph node biopsy improves surgical management of cervical cancer	109
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL	108
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma	107
Newly approved cancer drugs in China — innovation and clinical benefit	105
Lung cancer in patients who have never smoked — an emerging disease	105
Claudin 18.2 as a novel therapeutic target	105

Clinical implications of T cell exhaustion for cancer immunotherapy	102
Enhancing immunotherapy with tumour-responsive nanomaterials	102
Targeted biopsy reduces detection of clinically insignificant cancer	101
T-DXd effective as second-line therapy in G/GEJ cancers	100
Second-line tarlatamab improves OS in SCLC	99
Less-frequent surveillance is noninferior to annual mammography	97
Reduced-volume radiotherapy for locally advanced NPC improves QOL without compromising efficacy	96
OS benefit with first-line datopotamab deruxtecan in advanced-stage TNBC	92
Barriers in access to oncology drugs — a global crisis	89
Advances in the management of metastatic gastric cancer: current strategies and emerging therapeutics	86
The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology	84
Translating biological insights into improved management of endometrial cancer	84
Patient value over patent value: the mandate for open-source oncology	81
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges	78
Two decades of advances in clinical oncology — lessons learned and future directions	76
SERENA-6: dynamic ctDNA assessment and the future of precision cancer medicine	76
BrECADD raises the bar in classical Hodgkin lymphoma	75
HSCT prolongs remission of high-risk CTCLs	73
Thermal ablation is safer than resection of colorectal liver lesions	71
Promising OS with oncolytic virotherapy	67
Zanidatamab shows promise as first-line therapy for advanced-stage HER2+ GEA	65
GPRC5D-CAR T cells active in MM	63
Promise with co-administration of CAR T cells	63
Efficacy of TILs confirmed	62
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	61
Nirogacestat effective in desmoid tumours	59
Overdiagnosis, competing morbidity and tumour biology in older women with breast cancer: building a case for active monitoring	58
Cured but breathless: the growing burden of DIILD in cancer survivors	58
Non-financial conflicts of interest	58
Exercise as a new therapeutic modality in oncology: CHALLENGE trial refines survivorship care	57
Multidisciplinary management of meningiomas in the era of precision oncology	57
Engineering platelets as cancer therapeutics	55
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	50
Exploiting bacteria for cancer immunotherapy	48
The current state of the art and future trends in RAS-targeted cancer therapies	45
Repotrectinib effective in ROS1-fusion-positive NSCLC	44
Problematic crossovers in cancer drug trials	41
KN046 shows tolerability and activity in TNBC	41
Neoadjuvant pembrolizumab improves outcomes	39
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	39
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	38
Clinical implementation of multi-cancer early detection tests: can we find a path forward?	38
Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes	37
The emerging roles of γδ T cells in cancer immunotherapy	36
Realizing the benefits of tumour-agnostic access requires a national health learning system	36
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges	35
Venetoclax–obinutuzumab combinations are effective in fit patients with CLL	34
CAR T cells induce durable remission of neuroblastoma	33
MARIPOSA demonstrates overall survival benefit from amivantamab–lazertinib	33
Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons	32
Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours	32
GPRC5D as a novel immunotherapeutic target in multiple myeloma	32
National value-based pricing negotiation for oncology drugs — lessons from China	32
The changing landscape of oncology clinical trials in Latin America	31
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma	30
Personalizing adjuvant therapy for patients with colorectal cancer	28
Treatment of NSCLC after chemoimmunotherapy — are we making headway?	28